Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory‐Head and Neck Module

A prospective longitudinal study to profile patient‐reported symptoms during radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) for head and neck cancer was performed. The goals were to understand the onset and trajectory of specific symptoms and their severity, identify clusters, and facilitate symptom interventions and clinical trial design.

[1]  A. Garden,et al.  The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. , 2008, International journal of radiation oncology, biology, physics.

[2]  J. Gilbert,et al.  Systemic and global toxicities of head and neck treatment , 2007, Expert review of anticancer therapy.

[3]  C. Cleeland,et al.  Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy , 2013, Quality of Life Research.

[4]  P. Fayers,et al.  The clinical significance of adaptation to changing health: A meta-analysis of response shift , 2006, Quality of Life Research.

[5]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[6]  B. Jeremic,et al.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. , 2007, International journal of radiation oncology, biology, physics.

[7]  Tito R Mendoza,et al.  Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module , 2007, Head & neck.

[8]  C. Fuller,et al.  High symptom burden prior to radiation therapy for head and neck cancer: A patient‐reported outcomes study , 2012, Head & neck.

[9]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[10]  J. Farrar,et al.  Core outcome domains for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[11]  J. Sloan,et al.  Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. , 2010, Journal of pain and symptom management.

[12]  G. Gunn,et al.  Late dysphagia after radiotherapy‐based treatment of head and neck cancer , 2012, Cancer.

[13]  C. Varricchio,et al.  NIH State-of-the-Science Statement on symptom management in cancer: pain, depression, and fatigue. , 2002, NIH consensus and state-of-the-science statements.

[14]  C. Cleeland,et al.  Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy , 2010, Brain, Behavior, and Immunity.

[15]  C. Cleeland,et al.  Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy , 2012, Brain, Behavior, and Immunity.

[16]  A. Garden,et al.  Importance of patient examination to clinical quality assurance in head and neck radiation oncology , 2006, Head & neck.